Mountain View, California, September 26, 2017 – QT Medical, the leader in ECG technology, has announced that its CEO, Dr. Ruey-Kang Chang, has been awarded the grand prize of Digital Health Challenge - a competition held by MedImmune. The competition was part of the Digital Health Transforming Drug Development Translational Science Forum, hosted annually by MedImmune, the global biologics research and development arm of AstraZeneca.
Asthmagram -- a wearable patch for objective assessment of asthma symptoms and therapeutic controls of children with asthma, was presented and recognized by a panel of prominent industry funding experts and executives. As the Digital Health Challenge winner, Dr. Ruey-Kang Chang will receive a $20,000 cash prize along with the partnering opportunities with MedImmune and AstraZeneca.
Competing under the idea of engaging in technologies to transform digital health, five finalists were selected from more than hundreds of companies, many of which are based in Silicon Valley and financed by venture capital. The companies were judged based on five selection criteria - Product, Technical Feasibility, Marketing/Strategy, Leadership Team, and Financial/Projection. The judges were Julia Belaya of Healthcare Innovation, Yan Cao of Diagnostics & Digital Health Catalyst, Alice Jacobs of Third Rock Ventures, Jane Osbourn of MedImmune, John Trainer of MedImmune, and Samuel Wu of Acuris Partners.
MedImmune is an American biotechnology company focusing on infection, oncology, cardiovascular/gastrointestinal disease, neuroscience, respiratory disease and inflammation -- in the areas of products specializing for Asthma. MedImmune is a subsidiary of UK-based pharmaceutical giant AstraZeneca. For more information, visit MedImmune's website at https://www.medimmune.com.
To learn more about MedImmune Digital Health Transforming Drug Development Translational Science Forum and the Digital Health Challenge, visit https://www.medimmunetsforum.com/Content/Program and https://medimmunetsforum.com/Content/DHC.